For the treatment of schizophrenia
INVEGA® SUSTENNA® safety profile— Weight change

Weight-change profile in the longer-term study1,7

Weight change

STUDY DESIGN: Results from the longer-term, placebo-controlled study of adult patients with schizophrenia. Patients received a 39-mg, 78-mg, or 156-mg dose of INVEGA® SUSTENNA® in a 33-week, open-label stabilization phase. Patients were then randomized to this same dose or to placebo in a variable-length, double-blind phase. Due to significant efficacy, the study was terminated early at the preplanned interim analysis.1,7

From the variable-length, double-blind phase of the longer-term study to endpoint, 6% of patients treated with INVEGA® SUSTENNA® had weight gain ≥7% of total body weight vs 3% of placebo-treated patients1

  • In the 33-week, open-label phase of this study, 12% of subjects treated with INVEGA® SUSTENNA® had weight gain ≥7% of total body weight1

Weight Gain: Significant weight gain has been reported with the use of INVEGA® SUSTENNA® and other atypical antipsychotics. Healthcare professionals should monitor patient weight gain.1